Doxycycline and Tigecycline: Two Friendly Drugs with a Low Association with Clostridium Difficile Infection

• Main Authors: Yuan-Pin Hung, Jen-Chieh Lee, Hsiao-Ju Lin, Hsiao-Chieh Liu, Yi-Hui Wu, Pei-Jane Tsai, Wen-Chien Ko
• Format: Article
• Language: English
• Published: MDPI AG 2015-06-01
• Series: Antibiotics
• Subjects: Clostridium difficile; doxycycline; tigecycline
• Online Access: http://www.mdpi.com/2079-6382/4/2/216

Clostridium difficile infection (CDI) is known to be associated with prior exposure to many classes of antibiotics. Standard therapy for CDI (i.e., metronidazole and vancomycin) is associated with high recurrence rates. Although tetracycline derivatives such as tetracycline, doxycycline or tigecycline are not the standard therapeutic choices for CDI, they may serve as an alternative or a component of combination therapy. Previous tetracycline or doxycycline usage had been shown to have less association with CDI development. Tigecycline, a broad-spectrum glycylcycline with potency against many gram-positive or gram-negative pathogens, had been successfully used to treat severe or refractory CDI. The in vitro susceptibility of C. difficile clinical isolates to tigecycline in many studies showed low minimal inhibitory concentrations. Tigecycline can suppress in vitro toxin production in both historical and hypervirulent C. difficile strains and reduce spore production in a dose-dependent manner. Tetracycline compounds such as doxycycline, minocycline, and tigecycline possess anti-inflammatory properties that are independent of their antibiotic activity and may contribute to their therapeutic effect for CDI. Although clinical data are limited, doxycycline is less likely to induce CDI, and tigecycline can be considered one of the therapeutic choices for severe or refractory CDI.